Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype.
暂无分享,去创建一个
G. Kayser | J. Seufert | N. Perakakis | K. Laubner | E. von Dobschuetz | O. Thomusch | L. Parsons | F. Billmann | F. Flohr | S. Rondot
[1] G. Valk,et al. Reply to: Breast cancer risk in MEN1 – a cancer genetics perspective , 2015, Clinical endocrinology.
[2] P. Brennan. Breast cancer risk in MEN1 – a cancer genetics perspective , 2015, Clinical endocrinology.
[3] S. O'meara,et al. Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing , 2015, Journal of Clinical Pathology.
[4] Z. Yin,et al. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma. , 2014, Journal of hepatology.
[5] V. Fendrich,et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. , 2014, The Journal of clinical endocrinology and metabolism.
[6] G. Valk,et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. , 2014, The New England journal of medicine.
[7] Yao Yang,et al. RETRACTED ARTICLE: MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN , 2014, Tumor Biology.
[8] G. Wilding,et al. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression , 2014, The Prostate.
[9] M. Brandi,et al. Sarcomatoid carcinoma of the kidney in a MEN1 patient: case report and genetic profile. , 2014, Endocrine journal.
[10] P. Chanson,et al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study. , 2013, Human molecular genetics.
[11] Michael R. Green,et al. MEN1 Is a Melanoma Tumor Suppressor That Preserves Genomic Integrity by Stimulating Transcription of Genes That Promote Homologous Recombination-Directed DNA Repair , 2013, Molecular and Cellular Biology.
[12] J. Bilezikian,et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.
[13] Qi Zhao,et al. Expression and subcellular localization of menin in human cancer cells. , 2012, Experimental and therapeutic medicine.
[14] Zijie Feng,et al. Menin represses malignant phenotypes of melanoma through regulating multiple pathways , 2011, Journal of cellular and molecular medicine.
[15] Zhao-Qi Wang,et al. Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice , 2010, BMC Cancer.
[16] B. Harding,et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia , 2009, Endocrine-related cancer.
[17] G. Valk,et al. Multiple Endocrine Neoplasia Type 1 (MEN 1) , 2009 .
[18] J. Cobb,et al. Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome , 2005, Molecular Cancer.
[19] G. Chrousos,et al. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. , 2002, The Journal of clinical endocrinology and metabolism.
[20] R. Weigel,et al. Genetic Analysis of a Papillary Thyroid Carcinoma in a Patient with MEN1 , 2001, Annals of Surgical Oncology.
[21] E. Fearon,et al. Cancer progression , 1999, Current Biology.